PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33105696-4	2020	Pharmacology with 2"(3")-O-(4-benzoylbenzoyl) adenosine 5"-triphosphate (BzATP) as agonist showed dose-dependent membranal pores on RPMI-8226 (p = 0.0027) and blockade with P2X7 receptor antagonists.	rpmi-8226	132-141	purinergic receptor P2X 7	Homo sapiens	173-186
33105696-6	2020	Chronic P2X7 receptor activation reduced RPMI-8226 viability (p = 0.0208).	rpmi-8226	41-50	purinergic receptor P2X 7	Homo sapiens	8-21
33105696-9	2020	As myeloma pathology depends on a positive and proximal interaction with bone, we show that P2X7 receptor on RPMI-8226 inhibited the myeloma-induced suppression on mineralization (p = 0.0286) and reversed the excessive osteoclastic resorption.	rpmi-8226	109-118	purinergic receptor P2X 7	Homo sapiens	92-105
24535016-9	2014	Combination of ZD55-TRAIL with the PI3K inhibitor LY294002 in RPMI-8226 cells inhibited the virus-mediated activation of mTOR and AKT, thus, promoting cell death.	rpmi-8226	62-71	TNF superfamily member 10	Homo sapiens	20-25
24535016-9	2014	Combination of ZD55-TRAIL with the PI3K inhibitor LY294002 in RPMI-8226 cells inhibited the virus-mediated activation of mTOR and AKT, thus, promoting cell death.	rpmi-8226	62-71	mechanistic target of rapamycin kinase	Homo sapiens	121-125
24535016-9	2014	Combination of ZD55-TRAIL with the PI3K inhibitor LY294002 in RPMI-8226 cells inhibited the virus-mediated activation of mTOR and AKT, thus, promoting cell death.	rpmi-8226	62-71	AKT serine/threonine kinase 1	Homo sapiens	130-133
35222421-8	2022	In NSG mice bearing RPMI-8226 tumors overexpressing TGF-beta, the B2ARM CAR mediated 100% tumor rejection and survival, superior infiltration of tumors on day 7 post CAR T treatment (%CD3+CAR+), and greater expression of IFN-gamma, TNF-alpha, Ki67, Granzyme B, and PD-1, as compared to tumor-infiltrating non-armored B2 CAR T-cells.	rpmi-8226	20-29	transforming growth factor alpha	Mus musculus	52-60
35222421-8	2022	In NSG mice bearing RPMI-8226 tumors overexpressing TGF-beta, the B2ARM CAR mediated 100% tumor rejection and survival, superior infiltration of tumors on day 7 post CAR T treatment (%CD3+CAR+), and greater expression of IFN-gamma, TNF-alpha, Ki67, Granzyme B, and PD-1, as compared to tumor-infiltrating non-armored B2 CAR T-cells.	rpmi-8226	20-29	nuclear receptor subfamily 1, group I, member 3	Mus musculus	72-75
35222421-8	2022	In NSG mice bearing RPMI-8226 tumors overexpressing TGF-beta, the B2ARM CAR mediated 100% tumor rejection and survival, superior infiltration of tumors on day 7 post CAR T treatment (%CD3+CAR+), and greater expression of IFN-gamma, TNF-alpha, Ki67, Granzyme B, and PD-1, as compared to tumor-infiltrating non-armored B2 CAR T-cells.	rpmi-8226	20-29	interferon gamma	Mus musculus	221-230
35222421-8	2022	In NSG mice bearing RPMI-8226 tumors overexpressing TGF-beta, the B2ARM CAR mediated 100% tumor rejection and survival, superior infiltration of tumors on day 7 post CAR T treatment (%CD3+CAR+), and greater expression of IFN-gamma, TNF-alpha, Ki67, Granzyme B, and PD-1, as compared to tumor-infiltrating non-armored B2 CAR T-cells.	rpmi-8226	20-29	tumor necrosis factor	Mus musculus	232-241
35222421-8	2022	In NSG mice bearing RPMI-8226 tumors overexpressing TGF-beta, the B2ARM CAR mediated 100% tumor rejection and survival, superior infiltration of tumors on day 7 post CAR T treatment (%CD3+CAR+), and greater expression of IFN-gamma, TNF-alpha, Ki67, Granzyme B, and PD-1, as compared to tumor-infiltrating non-armored B2 CAR T-cells.	rpmi-8226	20-29	antigen identified by monoclonal antibody Ki 67	Mus musculus	243-247
35222421-8	2022	In NSG mice bearing RPMI-8226 tumors overexpressing TGF-beta, the B2ARM CAR mediated 100% tumor rejection and survival, superior infiltration of tumors on day 7 post CAR T treatment (%CD3+CAR+), and greater expression of IFN-gamma, TNF-alpha, Ki67, Granzyme B, and PD-1, as compared to tumor-infiltrating non-armored B2 CAR T-cells.	rpmi-8226	20-29	granzyme B	Mus musculus	249-259
35222421-8	2022	In NSG mice bearing RPMI-8226 tumors overexpressing TGF-beta, the B2ARM CAR mediated 100% tumor rejection and survival, superior infiltration of tumors on day 7 post CAR T treatment (%CD3+CAR+), and greater expression of IFN-gamma, TNF-alpha, Ki67, Granzyme B, and PD-1, as compared to tumor-infiltrating non-armored B2 CAR T-cells.	rpmi-8226	20-29	programmed cell death 1	Mus musculus	265-269
35222421-8	2022	In NSG mice bearing RPMI-8226 tumors overexpressing TGF-beta, the B2ARM CAR mediated 100% tumor rejection and survival, superior infiltration of tumors on day 7 post CAR T treatment (%CD3+CAR+), and greater expression of IFN-gamma, TNF-alpha, Ki67, Granzyme B, and PD-1, as compared to tumor-infiltrating non-armored B2 CAR T-cells.	rpmi-8226	20-29	nuclear receptor subfamily 1, group I, member 3	Mus musculus	320-323
35222421-9	2022	In NSG RPMI-8226 xenograft model in which tumors were additionally supplemented with TGF-beta injections on days -1 through 11 of CAR T treatment, the B2ARM CAR T cells rejected tumors faster than the non-armored B2 CARs, and showed greater numbers of CD3+ and CD3+CAR+, central memory (CD45RO+CD62L+) and effector memory (CD45RO+CD62L-) T cells in the peripheral blood 18 days after treatment.	rpmi-8226	7-16	nuclear receptor subfamily 1, group I, member 3	Mus musculus	157-160
33147936-8	2021	Therapeutic targeting of CCR1 with the inhibitor CCX9588 significantly reduced OPM2 or RPMI-8226 dissemination in intratibial xenograft models.	rpmi-8226	87-96	chemokine (C-C motif) receptor 1	Mus musculus	25-29
32388607-2	2021	We found that Twist1 was highly expressed in clinical multiple myeloma (MM) cells, and explored its roles in proliferation and apoptosis in human MM cell lines U266 and RPMI-8226.	rpmi-8226	169-178	twist family bHLH transcription factor 1	Homo sapiens	14-20
27779672-0	2016	Knockdown of macrophage inhibitory cytokine-1 in RPMI-8226 human multiple myeloma cells inhibits osteoclastic differentiation through inhibiting the RANKL-Erk1/2 signaling pathway.	rpmi-8226	49-58	growth differentiation factor 15	Homo sapiens	13-45
27779672-0	2016	Knockdown of macrophage inhibitory cytokine-1 in RPMI-8226 human multiple myeloma cells inhibits osteoclastic differentiation through inhibiting the RANKL-Erk1/2 signaling pathway.	rpmi-8226	49-58	TNF superfamily member 11	Homo sapiens	149-154
27779672-0	2016	Knockdown of macrophage inhibitory cytokine-1 in RPMI-8226 human multiple myeloma cells inhibits osteoclastic differentiation through inhibiting the RANKL-Erk1/2 signaling pathway.	rpmi-8226	49-58	mitogen-activated protein kinase 3	Homo sapiens	155-161
23804425-2	2013	EXPERIMENTAL DESIGN: We have evaluated the expression levels of cMET/phospho-cMET (p-cMET) and the activity of the novel selective p-cMET inhibitor (SU11274) in multiple myeloma cells, either sensitive (RPMI-8226 and MM.1S) or resistant (R5 and MM.1R) to anti-multiple myeloma drugs, in primary plasma cells and in multiple myeloma xenograft models.	rpmi-8226	203-212	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	64-68
11340567-3	2001	We have shown that irradiation of the human myeloma cell line RPMI-8226 induced apoptosis as determined by DNA degradation, cytochrome c release into cytoplasm and BCL-2 caspase-mediated cleavage.	rpmi-8226	62-71	cytochrome c, somatic	Homo sapiens	124-136
11340567-3	2001	We have shown that irradiation of the human myeloma cell line RPMI-8226 induced apoptosis as determined by DNA degradation, cytochrome c release into cytoplasm and BCL-2 caspase-mediated cleavage.	rpmi-8226	62-71	BCL2 apoptosis regulator	Homo sapiens	164-169
7512529-6	1994	BU-33 was the best inhibitor of CD23-liposome binding to the CD21-positive cell line RPMI-8226 when compared to the other anti-CD21 mAb tested.	rpmi-8226	85-94	Fc epsilon receptor II	Homo sapiens	32-36
7512529-6	1994	BU-33 was the best inhibitor of CD23-liposome binding to the CD21-positive cell line RPMI-8226 when compared to the other anti-CD21 mAb tested.	rpmi-8226	85-94	complement C3d receptor 2	Homo sapiens	61-65
8218946-1	1993	The early events following the ligation of interleukin-4 (IL-4) to the plasmacytoma cell line RPMI-8226 were analysed as a model of action for this interleukin on differentiated cells of the B lymphocyte lineage.	rpmi-8226	94-103	interleukin 4	Homo sapiens	43-56
8218946-1	1993	The early events following the ligation of interleukin-4 (IL-4) to the plasmacytoma cell line RPMI-8226 were analysed as a model of action for this interleukin on differentiated cells of the B lymphocyte lineage.	rpmi-8226	94-103	interleukin 4	Homo sapiens	58-62